Patents by Inventor Gaiying ZHAO

Gaiying ZHAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KRAS INHIBITORS
    Publication number: 20240043451
    Abstract: The present invention provides compounds of the formula: wherein A, B, D1, X, Y, Z, G, R1, R2, and R3a are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.
    Type: Application
    Filed: March 24, 2023
    Publication date: February 8, 2024
    Inventors: David Anthony BARDA, Jolie Anne BASTIAN, Kelly Wayne FURNESS, Deqi GUO, James Robert HENRY, Richard Duane JOHNSTON, Jason Eric LAMAR, Tao LIU, Michael John RODRIGUEZ, Almudena RUBIO, Chong SI, Gaiying ZHAO, Mohammad Sadegh ZIA-EBRAHIMI, Matthew Patrick BAUMGARTNER, Isabel ROJO, Mario BARBERIS, Santiago CARBALLARES MARTIN, Pablo GARCIA LOSADA, Sonia Maria GUTIERREZ SANFELICIANO, Wenceslao LUMERAS AMADOR, Victoriano MOLERO FLOREZ, Maria Lourdes PRIETO VALLEJO
  • Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus
    Patent number: 11891400
    Abstract: The present invention provides a compound of Formula I: wherein R is methyl or ethyl; or a pharmaceutically acceptable salt thereof useful for treating psoriasis or systemic lupus erythematosus.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: February 6, 2024
    Assignee: Eli Lilly and Company
    Inventors: Zhaogen Chen, Jon Andre Erickson, Gaiying Zhao
  • PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS
    Publication number: 20210188861
    Abstract: The present invention provides a compound of Formula I: wherein R is methyl or ethyl; or a pharmaceutically acceptable salt thereof useful for treating psoriasis or systemic lupus erythematosus.
    Type: Application
    Filed: September 4, 2019
    Publication date: June 24, 2021
    Inventors: Zhaogen CHEN, Jon Andre ERICKSON, Gaiying ZHAO
  • 1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer
    Patent number: 10759786
    Abstract: The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioblastoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: September 1, 2020
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Jiehao Chen, Jeffrey Daniel Cohen, James Robert Henry, William Thomas McMillen, Bradley Earl Reaman, Almudena Rubio, Daniel Jon Sall, Gaiying Zhao
  • Notch pathway signaling inhibitor compounds
    Patent number: 10450317
    Abstract: The present invention provides the following compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing said compounds useful as a Notch pathway signaling inhibitor for the treatment of named cancers, sensorineural hearing loss caused by auditory hair cell loss, and inducing auditory hair cell generation.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: October 22, 2019
    Assignees: Eli Lilly and Company, Audion Therapeutics
    Inventors: Julia Marie Clay, Albert Edge, Philip Arthur Hipskind, John C. Gill, Bharvin Kumar Patel, Helmuth Hendrikus Gerardus Van Es, Aaron D. Wrobleski, Gaiying Zhao
  • 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-IH-INDOLE COMPOUNDS FOR TREATING CANCER
    Publication number: 20190161477
    Abstract: The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioblastoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
    Type: Application
    Filed: May 31, 2017
    Publication date: May 30, 2019
    Inventors: Jolie Anne BASTIAN, Jiehao CHEN, Jeffrey Daniel COHEN, James Robert HENRY, William Thomas MCMILLEN, Bradley Earl REAMAN, Almudena RUBIO, Daniel Jon SALL, Gaiying ZHAO
  • NOTCH PATHWAY SIGNALING INHIBITOR COMPOUNDS
    Publication number: 20180148456
    Abstract: The present invention provides the following compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing said compounds useful as a Notch pathway signaling inhibitor for the treatment of named cancers, sensorineural hearing loss caused by auditory hair cell loss, and inducing auditory hair cell generation.
    Type: Application
    Filed: July 1, 2016
    Publication date: May 31, 2018
    Inventors: Julia Marie Clay, Albert Edge, Philip Arthur Hipskind, John C. Gill, Bharvin Kumar Patel, Helmuth Hendrikus Gerardus Van Es, Aaron D. Wrobleski, Gaiying Zhao
  • ERK inhibitors
    Patent number: 9879029
    Abstract: The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: January 30, 2018
    Assignee: Eli Lilly and Company
    Inventors: Guillermo S. Cortez, Sajan Joseph, Johnathan Alexander McLean, William Thomas McMillen, Michael John Rodriguez, Gaiying Zhao
  • 2,3-dihydro-1H-indole compounds
    Patent number: 9872853
    Abstract: The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: January 23, 2018
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Jiehao Chen, Jeffrey Daniel Cohen, James Robert Henry, William Thomas McMillen, Bradley Earl Reaman, Almudena Rubio, Daniel Jon Sall, Gaiying Zhao
  • 2,3-DIHYDRO-1H-INDOLE COMPOUNDS
    Publication number: 20170354641
    Abstract: The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
    Type: Application
    Filed: May 31, 2017
    Publication date: December 14, 2017
    Inventors: Jolie Anne Bastian, Jiehao Chen, Jeffrey Daniel Cohen, James Robert Henry, William Thomas McMillen, Bradley Earl Reaman, Almudena Rubio, Daniel Jon Sall, Gaiying Zhao
  • ERK INHIBITORS
    Publication number: 20170267691
    Abstract: The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.
    Type: Application
    Filed: December 15, 2015
    Publication date: September 21, 2017
    Inventors: Guillermo S. Cortez, Sajan Joseph, Johnathan Alexander McLean, William Thomas McMillen, Michael John Rodriguez, Gaiying Zhao
  • Aminopyridyloxypyrazole compounds
    Patent number: 9617243
    Abstract: The present invention relates to novel aminopyridyloxypyrazole compounds that inhibit the activity of transforming growth factor beta receptor 1 (TGF?R1), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, preferably colon cancer, melanoma, hepatocellular carcinoma, renal cancer, glioblastoma, pancreatic cancer, myelodysplastic syndrome, lung cancer, and gastric cancer, and/or fibrosis, preferably liver fibrosis and chronic kidney disease.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: April 11, 2017
    Assignee: Eli Lilly and Company
    Inventors: William T. McMillen, Sajan Joseph, Huaxing Pei, Jason Scott Sawyer, Gaiying Zhao, David A. Coates, Craig D. Wolfangel
  • ERK inhibitors
    Patent number: 9469652
    Abstract: The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: October 18, 2016
    Assignee: Eli Lilly and Company
    Inventors: Guillermo S. Cortez, Sajan Joseph, Johnathan Alexander McLean, William T. McMillen, Michael John Rodriguez, Gaiying Zhao
  • ERK INHIBITORS
    Publication number: 20160176896
    Abstract: The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.
    Type: Application
    Filed: December 16, 2015
    Publication date: June 23, 2016
    Inventors: Guillermo S. Cortez, Sajan Joseph, Johnathan Alexander McLean, William T. McMillen, Michael John Rodriguez, Gaiying Zhao
  • AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS
    Publication number: 20160096823
    Abstract: The present invention relates to novel aminopyridyloxypyrazole compounds that inhibit the activity of transforming growth factor beta receptor 1 (TGF?R1), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, preferably colon cancer, melanoma, hepatocellular carcinoma, renal cancer, glioblastoma, pancreatic cancer, myelodysplastic syndrome, lung cancer, and gastric cancer, and/or fibrosis, preferably liver fibrosis and chronic kidney disease.
    Type: Application
    Filed: September 30, 2015
    Publication date: April 7, 2016
    Inventors: William T. MCMILLEN, Sajan JOSEPH, Saravanan PARTHASARATHY, Huaxing PEI, Jason Scott SAWYER, Douglas W. BEIGHT, Gaiying ZHAO, David A. COATES, Craig D. WOLFANGEL
  • ERK inhibitors
    Patent number: RE48635
    Abstract: The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: July 13, 2021
    Assignee: Eli Lilly and Company
    Inventors: Guillermo S. Cortez, Sajan Joseph, Johnathan Alexander McLean, William T. McMillen, Michael John Rodriguez, Gaiying Zhao